Gene Therapy for Cardiovascular Disease Market Poised for Rapid Growth with Promising Clinical Results in Heart and Vascular Disorder Treatments

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Gene Therapy on Cardiovascular Disease Market - (By Type (Viral Gene Therapy, Non-Viral Gene Therapy), By Application (Heart Disease, Vascular Disease)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Gene Therapy on Cardiovascular Disease Market is predicted to grow with a CAGR of 67.4% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2451

Cardiovascular disease gene therapy involves the introduction of genetic material into a patient's cells to treat or prevent conditions such as coronary artery disease. The primary aim of gene therapy in this context is to enhance the function of the heart and blood vessels by addressing genetic defects or modifying gene expression. One common method for delivering therapeutic genes to cardiac or arterial cells is through the use of viral vectors. Clinical trials have shown that gene therapy has led to improvements in certain cardiovascular conditions, including heart failure and inherited heart diseases. This growing body of research and development in gene therapy is garnering increased interest from both public and private sectors. As a result, the market for gene therapy in coronary artery disease is expected to expand in the coming years.

In addition to traditional gene therapies, mRNA-based gene treatments are emerging as an innovative approach. Unlike conventional methods, which involve the direct transfer of therapeutic genes to target cells, mRNA therapies deliver synthetic mRNA molecules that instruct target cells to produce the desired therapeutic protein. This approach offers several advantages, including improved safety and simplified production processes. Furthermore, mRNA-based gene therapies are more accessible due to their lower costs and faster manufacturing timelines compared to traditional gene therapies. However, a key challenge to the growth of the global gene therapy and cardiovascular disease market is the difficulty in retaining skilled talent, which remains a significant barrier to maintaining a stable workforce in this highly specialized field.

List of Prominent Players in the Gene Therapy on Cardiovascular Disease Market:
• Biogen
• Novartis
• Gilead Sciences
• Sarepta Therapeutics
• Alnylam Pharmaceuticals
• Amgen
• Spark Therapeutics
• Akcea Therapeutics
• Sunway Biotech
• bluebird bio
• SIBIONO
• AnGes
• Orchard Therapeutics
• Other Market Players

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics:
Drivers:
The increasing demand for gene therapy in the cardiovascular disease market is primarily driven by the rising prevalence of chronic conditions, including cancer and rare genetic disorders. As more individuals recognize gene therapy as a viable treatment option, particularly for cancer, and with growing governmental support for this field, the market is seeing significant momentum. These factors collectively contribute to the accelerating demand for gene therapy solutions in cardiovascular care.

Challenges:
Key challenges hindering market growth include high investment requirements, a shortage of skilled professionals, and a lack of standardized protocols, especially in emerging markets where regulatory frameworks have been delayed due to lockdowns and isolation measures. The production and delivery of gene therapies are costly due to the advanced and emerging nature of the technology, with expenses often passed on to patients. This can limit access to treatment, particularly for those without sufficient insurance or financial resources. Additionally, the absence of established payment standards and limited insurance coverage further exacerbate the cost barrier. Insurers and healthcare providers may be hesitant to fund gene therapies, especially for rare diseases, due to concerns over long-term safety and efficacy, which could impede the market's growth. Furthermore, the COVID-19 pandemic has had a profound impact on the healthcare sector, disrupting clinical trials and supply chains, particularly in the gene therapy space for cardiovascular diseases.

Regional Trends:
The North American market for gene therapy in cardiovascular diseases is expected to hold a significant market share, driven by an increasing incidence of cardiovascular diseases, substantial investments in research and development, the introduction of innovative technologies, and the implementation of new government initiatives. Additionally, growing healthcare expenditures are also contributing to market expansion in this region. In Europe, the market has also seen substantial growth, fueled by factors such as a large patient population, higher rates of infectious diseases, increasing awareness of gene therapy, a higher incidence of cancer, and significant involvement in research and development efforts.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2451

Recent Developments:
• In Nov 2023, Amgen presented new information at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, which further supports the safety and effectiveness of Repatha® (evolocumab) based on the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial. The presentations will specifically address the reduction of LDL "bad" cholesterol (LDL-C), which is a well-known risk factor for cardiovascular disease (CVD).
• In Aug 2023, Lexeo Therapeutics received a strategic investment from Sarepta Therapeutics to aid in the advancement of Lexeo's cardiovascular gene therapies. The companies will investigate the creation of innovative gene therapy candidates for various cardiovascular diseases as part of this investment.

Segmentation of Gene Therapy on Cardiovascular Disease Market-
By Type-
• Viral Gene Therapy
• Non-Viral Gene Therapy
By Application-
• Heart Disease
• Vascular Disease
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/gene-therapy-on-cardiovascular-disease-market/2451

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.